Drugs / RLD2007
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05862090 | Apr → May 2023 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT05155995 | Sep 2021 → Nov 2022 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT04946903 | Jun → Aug 2021 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05155995 ↗ |
| Route | Oral | “RLD2301 and RLD2007 after oral administration” NCT05862090 ↗ |